Delivery Order SPE2DB20D3103-SPE2DB22FN4B1
- Not listed
- This federal contract award to Amerisourcebergen Drug Corp, a subsidiary of Amerisourcebergen Corporation, is for the delivery of Verapamil ER 120 mg tablets to the Defense Logistics Agency (DLA). The $2,326.88 firm fixed-price delivery order has a completion date of May 21, 2024. Amerisourcebergen holds a $999,999,999.00 Indefinite Delivery Contract (IDC) with DLA Troop Support Medical to provide a wide range of pharmaceutical products and medical supplies to the Department of Defense globally....
- This federal contract award was issued by the Defense Logistics Agency (DLA) to Amerisourcebergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The $1,205.76 firm fixed-price delivery order is for the supply of 100 units of Verapamil ER 120 mg tablets. This contract is part of a larger $999,999,999 Indefinite Delivery Contract (IDC) held by Amerisourcebergen with the DLA Troop Support Medical, which serves as a primary vehicle for providing a comprehensive...
- This federal contract award was issued by the Defense Logistics Agency (DLA) to Amerisourcebergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The $1,525.58 Firm Fixed Price Delivery Order covers the provision of VERAPAMIL ER PM 300 MG CAPSULE 100S, a cardiovascular medication, to support military healthcare programs. Amerisourcebergen holds a $999,999,999 Indefinite Delivery Contract (IDC) with the DLA Troop Support Medical, which serves as a primary...
- This federal contract award, with ID SPE2DX15D3012|SPE2DX24F8SL7, was issued by the Defense Logistics Agency (DLA) Troop Support Medical to the prime contractor Amerisourcebergen Drug Corp, Corporate Office Division. The contract is for the delivery of Verapamil 5 mg/2 ml vials, with a total ceiling value of $2,321.94. It is a firm fixed-price delivery order contract with an ultimate completion date of August 2, 2024. Amerisourcebergen, a major pharmaceutical distributor, has been awarded this...
- This federal contract award to Amerisourcebergen Drug Corp, a subsidiary of Cencora, Inc., is a delivery order worth $4,722.50 from the Defense Logistics Agency (DLA) Troop Support Medical. The contract is for the delivery of various pharmaceutical products and medical supplies, including specialty medications, brand-name and generic drugs, vaccines, syringes, vials, and other critical care items. Amerisourcebergen holds a significant Indefinite Delivery Contract (IDC) with the DLA Troop Support...
- This federal contract award to Amerisourcebergen Drug Corp, a subsidiary of Cencora, Inc., is a delivery order valued at $1,044.96 issued by the Defense Logistics Agency (DLA) Troop Support Medical. The contract covers the provision of various pharmaceutical products and medical supplies, including specialty medications, brand-name and generic drugs, vaccines, syringes, vials, and test kits across multiple therapeutic areas. Amerisourcebergen holds a significant Indefinite Delivery Contract...
- This federal contract award to Amerisourcebergen Drug Corp, a subsidiary of Cencora, Inc., is a Delivery Order valued at $9,331.21 for pharmaceutical and medical supply products. The contract was awarded by the Defense Logistics Agency (DLA) and has no set-aside designation, indicating full and open competition. Amerisourcebergen holds a significant Indefinite Delivery Contract (IDC) with the DLA Troop Support Medical, valued at up to $999,999,999.00 through November 2026. This IDC serves as the...
- This federal contract award to Amerisourcebergen Drug Corp, a subsidiary of Cencora, Inc., is for the delivery of a variety of pharmaceutical products and medical supplies to support the U.S. Department of Defense (DoD) and Department of Veterans Affairs (VA) healthcare programs. The contract, valued at $2,141.44, was awarded by the Defense Logistics Agency (DLA) Troop Support Medical. Amerisourcebergen holds a significant $999,999,999 Indefinite Delivery Contract (IDC) with the DLA Troop...
- This federal contract award was issued by the Defense Logistics Agency (DLA) to Amerisourcebergen Drug Corp, a subsidiary of Cencora, Inc. The $11,319.86 firm-fixed-price delivery order contract provides pharmaceutical products, including the medication Verzenio 100 mg tablets, to support government healthcare programs. The contract has a period of performance through February 1, 2024. Amerisourcebergen holds a significant $999,999,999 Indefinite Delivery Contract (IDC) with the DLA Troop...
- This federal contract award, valued at $468,050.72, was issued by the Defense Logistics Agency (DLA) to Amerisourcebergen Drug Corp, a subsidiary of Cencora, Inc. The contract is a delivery order to provide pharmaceutical products and medical supplies, including specialty medications, brand-name drugs, generic pharmaceuticals, and various medical devices and equipment. Amerisourcebergen holds a significant Indefinite Delivery Contract (IDC) with the DLA Troop Support Medical, valued at up to...
- SPE2DB20D3103Indefinite Delivery Contract
- SPE2DB20D3103-SPE2DB22FN4B1Delivery Order
This federal contract award to Amerisourcebergen Drug Corp, a subsidiary of Cencora, Inc., is a delivery order valued at $9,568.68 for the supply of 4,556,952,350 units of Verapamil ER 240 mg tablets. The award was made by the Defense Logistics Agency (DLA), a component of the Department of Defense, and does not have a set-aside designation, indicating open competition. Amerisourcebergen holds a significant Indefinite Delivery Contract (IDC) with the DLA Troop Support Medical, valued at up to $999,999,999.00 through November 2026. This IDC serves as the primary vehicle for the company to deliver a comprehensive range of pharmaceutical products and medical supplies to support military healthcare programs globally. The contract covers a variety of critical medical commodities, including specialty medications, brand-name and generic drugs, vaccines, syringes, vials, and test kits across multiple therapeutic areas. Additionally, Amerisourcebergen maintains a separate IDC with the Department of Justice Federal Bureau of Investigation, valued at up to $750,000 through May 2024, for similar medical products and prescription drugs.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | Not listed | $9.6k | 4/20/22 |